戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  anti-CD40L monoclonal antibody were used as tolerogen.
2 ry CD8 T cells in mice to these two forms of tolerogen.
3 tructure, location, and concentration of the tolerogen.
4 T cells from strong stimulation by exogenous tolerogen.
5 sing novel TCRs that no longer recognize the tolerogen.
6  alternate TCR that no longer recognizes the tolerogen.
7 e potency and density of MHC class I-peptide tolerogen.
8 ry and is driven by a peripherally expressed tolerogen.
9 ells, thereby converting an immunogen into a tolerogen.
10  target epitopes are not available as B cell tolerogens.
11 re still susceptible to autoantigen-specific tolerogens.
12 distinct from naked peptide or protein-based tolerogens.
13 nduction of apoptosis in TNP-spl, making the tolerogen 100 times more potent.
14 de in IFA was administered parenterally as a tolerogen, after the development of a primary T cell imm
15 Ig-myelin oligodendrocyte glycoprotein (MOG) tolerogen, an Ig carrying the MOG35-55 peptide.
16 ble to tolerance induction, both the form of tolerogen and location of the T cells can determine thei
17 vation and memory markers are induced by the tolerogen and may exert their influence via cytokines to
18 e fact that they are both driven by the same tolerogen and restricted to mature CD4(+) T cells.
19 T cells can determine their accessibility to tolerogen and the degree to which they are successfully
20 lin basic protein are nevertheless effective tolerogens and are able to anergize autoreactive T cells
21 lagellin challenge antigen and a murine IgG1 tolerogen, both expressing the lambda repressor epitope
22 m for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challe
23                          Short peptide-based tolerogens, devoid of immunogenic and pathogenic potenti
24                         A phase I trial of a tolerogen directed at anti-beta2-glycoprotein I antibodi
25                                    The first tolerogen, directed at anti-dsDNA responses in SLE, did
26 cell death of DC and that IL-12 converts the tolerogen DNTB into an immunogen by preventing DNTB-indu
27  to DNFB, showing that IL-12 can convert the tolerogen DNTB into an immunogen.
28                                        Thus, tolerogen-driven receptor revision in peripheral T cells
29 t Th2 cells displayed reduced motility after tolerogen exposure similar to Th1 cells after immunizati
30  by altering the affinity of the peptide-MHC tolerogen for TCR, we have confirmed that this mechanism
31             Donor-derived sMHC are potential tolerogens for down-regulating the cytotoxic T-cell resp
32  that such vaccines may serve as Ag-specific tolerogens for the treatment of autoimmune disease.
33                             We developed LIT tolerogens from native respiratory allergens, which indu
34                                   Two B cell tolerogens have been used in human trials.
35  peptide, however, by 48 h after exposure to tolerogen, IL-2 production dropped and was replaced by h
36    Selected analogue peptides were tested as tolerogens in neonatal mice.
37 imaging, and T cell behavior was analyzed on tolerogen-induced modulation.
38 eatment on T cells in vivo demonstrated that tolerogen injection resulted in rapid T cell activation
39 ely, the data suggest that multiple receptor-tolerogen interactions regulate autoreactive cells in th
40            In TCRbeta chain transgenic mice, tolerogen-mediated chronic peripheral selection against
41                  We propose that the primary tolerogen of dual reactive B cells in this model is not
42 tion why the same proteins can act either as tolerogens or as allergens.
43 l is not ssDNA, but a strongly cross-linking tolerogen, presumably basement membrane laminin, that tr
44 ept that LIT with synthetically mannosylated tolerogens provides a rapid, safe, and effective approac
45 s strongly suggest that TCR revision rescues tolerogen-reactive peripheral T cells from deletion.
46 responding in vivo, Ndfip1 was necessary for tolerogen-reactive T cells to exit cell cycle after one
47 ymphoid organs rapidly up-regulate PD-1 upon tolerogen recognition.
48                        RF B cells exposed to tolerogen remain competent to secrete RF in vitro if pro
49  upon lymphorepletion even in the absence of tolerogen (self-antigen), challenging the prevailing par
50  33D1 was 100- to 1000-fold more potent as a tolerogen than an isotype-matched control rat IgG2b mAb.
51  as a unique class of inflammation-dependent tolerogens that are mechanistically distinct from naked
52                      Cells are driven by the tolerogen to enter one of two tolerance pathways, deleti
53 otic death might provide a primary source of tolerogen to shape the immune repertoire, or be the targ
54 issue-derived CII when given as i.v. or oral tolerogens to suppress arthritis.
55 graft reactive CD4(+) T cells transferred to tolerogen-treated recipients at the time of transplantat
56 termed OVA-psigma1, was developed to enhance tolerogen uptake.
57 vious studies using adult splenocytes as the tolerogen, we achieved a higher frequency of tolerance w
58 nitrophenyl-coupled splenocytes (TNP-spl) as tolerogen, we found that Fas signaling for apoptosis in
59                  A panel of analogues of the tolerogen were tested for their capacity to terminate th
60 ts such as anti-BlyS, anti-CD154, and B cell tolerogens will also be covered.
61 ior to inflammation and can be expanded with tolerogen without further differentiation.